Skip to main content
Industry News
Gene editing partnership broadened to include hemophilia

Regeneron Pharmaceuticals and Intellia Therapeutics announced they are widening the scope of their gene editing collaboration made four years ago to include projects for the treatment of hemophilia. As part of the expanded deal, Regeneron will pay Intellia $100 million in exchange for its use of the latter's cell re-engineering technology for the development and commercialization of hemophilia therapies.

Full Story: